MedTrace Logo

Community-based Neuroendocrine Tumor (NET) Research Study

NCT02730104 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-06-26

No results posted yet for this study

Summary

The purpose of this trial is to assess time to disease progression of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors treated with Lanreotide Depot. This is an observational study therefore all data collected will be in accordance with the routine practice of physicians.

Conditions

  • Gastroenteropancreatic Neuroendocrine Tumors

Sponsors & Collaborators

Principal Investigators

  • Ipsen Medical Director · Ipsen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-23
Primary Completion
2020-05-13
Completion
2020-05-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02730104 on ClinicalTrials.gov